We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Sleep Disorder Linked with Abnormal Lipid Levels

By LabMedica International staff writers
Posted on 05 Sep 2018
Print article
Image: An illustration of obstructive sleep apnea compared to normal breathing during sleep (Photo courtesy of Mayo Clinic).
Image: An illustration of obstructive sleep apnea compared to normal breathing during sleep (Photo courtesy of Mayo Clinic).
Obstructive sleep apnea is a disorder in which breathing is repetitively interrupted during sleep due to collapse of the upper airway. An apnea is defined as complete cessation of breathing lasting 10 seconds or greater.

Dyslipidemia is an abnormal amount of lipids such as triglycerides, cholesterol and/or fat phospholipids in the blood. Both obstructive sleep apnea (OSA) and dyslipidemia are independent risk factors for cardiovascular disease.

An international team of investigators led by scientists at the Sahlgrenska Academy (Gothenburg, Sweden) carried out a cross‐sectional analysis that included 8,592 patients without physician‐diagnosed hyperlipidemia or reported intake of a lipid‐lowering drug (age 50.1 ± 12.7 years, 69.1% male, BMI: 30.8 ± 6.6 kg/m2, mean apnea–hypopnea index (AHI): 25.7 ± 25.9 events/hour). The independent relationship between measures of OSA (AHI, oxygen desaturation index (ODI), mean and lowest oxygen saturation) and lipid profile (total cholesterol (TC), high‐density was calculated.

The team reported that there was a dose response relationship between TC and ODI (mean ± SE (mg/dL): 180.33 ± 2.46, 184.59 ± 2.42, 185.44 ± 2.42 and 185.73 ± 2.44; across ODI quartiles I–IV). Triglycerides (TG) and low-density lipoprotein cholesterol (LDL-C) concentrations were better predicted by AHI than by ODI. High-density lipoprotein-cholesterol (HDL‐C) was significantly reduced in the highest AHI quartile (mean ± SE (mg/dL): 48.8 ± 1.49 versus 46.50 ± 1.48; AHI quartile I versus IV). Morbid obesity was associated with lower TC and higher HDL‐C values. Lipid status was influenced by geographical location with the highest TC concentration recorded in Northern Europe.

The authors concluded that OSA severity was independently associated with cholesterol and TG concentrations. HDL‐C, LDL‐C, and fasting TG was determined by means of general linear model analysis. Dr. Ludger Grote, MD, PhD, a professor and senior author of the study, said, “Our data clearly suggest that sleep apnea may have a negative impact on lipid levels, which may in part explain the association between sleep apnea and increased risk for cardiovascular disease. Patients with sleep apnea therefore need careful management of all cardiovascular risk factors including hyperlipidemia.” The study was published on August 21, 2018, in the journal Respirology.

Related Links:
Sahlgrenska Academy

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunofluorescence Analyzer
MPQuanti
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.